Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II

Background. Enzyme replacement therapy (ERT) with iduronate-2-sulfatase recombinant forms (idursulfase and idursulfase beta) is effective for the management of mucopolysaccharidosis type II (MPS II). Patients with Hunter syndrome require lifelong ERT that can negate endogenous enzyme deficiency. How...

Full description

Bibliographic Details

Published in:	Педиатрическая фармакология
Main Authors:	Julia G. Levina, Nato D. Vashakmadze, Leyla S. Namazova-Baranova, Elena A. Vishneva, Mariya S. Karaseva, Natalia V. Zhurkova, Kamilla E. Efendieva, Anna A. Alekseeva, Vera G. Kalugina, Artur V. Zaz’yan
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2022-07-01
Subjects:	mucopolysaccharidosis type ii hunter syndrome enzyme replacement therapy idursulfase idursulfase beta drug allergy urticaria children clinical case
Online Access:	https://www.pedpharma.ru/jour/article/view/2178